Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

John S. Sack(Bristol-Myers Squibb (United States)), Kevin Kish(Bristol-Myers Squibb (United States)), Chihuei Wang(Bristol-Myers Squibb (United States)), Ricardo M. Attar(Bristol-Myers Squibb (United States)), Susan E. Kiefer(Bristol-Myers Squibb (United States)), Yongmi An(Bristol-Myers Squibb (United States)), Ginger Wu(Bristol-Myers Squibb (United States)), Julie E. Scheffler(Bristol-Myers Squibb (United States)), Mark Salvati(Bristol-Myers Squibb (United States)), Stanley R. Krystek(Bristol-Myers Squibb (United States)), Roberto Weinmann(Bristol-Myers Squibb (United States)), Howard Einspahr(Bristol-Myers Squibb (United States))
Proceedings of the National Academy of Sciences
April 24, 2001
Cited by 485Open Access
Full Text

Abstract

The structures of the ligand-binding domains (LBD) of the wild-type androgen receptor (AR) and the T877A mutant corresponding to that in LNCaP cells, both bound to dihydrotestosterone, have been refined at 2.0 A resolution. In contrast to the homodimer seen in the retinoid-X receptor and estrogen receptor LBD structures, the AR LBD is monomeric, possibly because of the extended C terminus of AR, which lies in a groove at the dimerization interface. Binding of the natural ligand dihydrotestosterone by the mutant LBD involves interactions with the same residues as in the wild-type receptor, with the exception of the side chain of threonine 877, which is an alanine residue in the mutant. This structural difference in the binding pocket can explain the ability of the mutant AR found in LNCaP cells (T877A) to accommodate progesterone and other ligands that the wild-type receptor cannot.


Related Papers

No related papers found

Powered by citation graph analysis